In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor κB pathways

Authors

  • Maria M Campos,

    1. Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Rua Ferreira Lima, 82, 88015–420, Florianópolis, SC, Brazil
    Search for more papers by this author
  • Glória E P Souza,

    1. Laboratory of Pharmacology, Faculty of Pharmacy, USP, Ribeirão Preto, Brazil
    Search for more papers by this author
  • João B Calixto

    Corresponding author
    1. Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Rua Ferreira Lima, 82, 88015–420, Florianópolis, SC, Brazil
    Search for more papers by this author

Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Rua Ferreira Lima, 82, 88015–420, Florianópolis, SC, Brazil. E-mail: Calixto@farmaco.ufsc.br

Abstract

  • Intradermal (i.d.) injection of cytokines, IL-1β and TNFα (5 ng, 60 and 30 min prior) produces a rapid onset up-regulation of des-Arg9-BK-mediated rat paw oedema. Here we analyse the mechanisms involved in des-Arg9-BK-induced oedema in animals pre-treated with IL-1β or TNFα.

  • Co-injection of anti-IL-1β, anti-TNFα and anti-IL-8 (50 ng) significantly inhibited des-Arg9-BK-induced oedema in animals pre-treated with IL-1β (65, 37 and 42%) or TNFα (39, 64, 25%). IL-1 receptor antagonist (IRA, 100 μg) or IL-10 (10 ng) inhibited the oedema caused by des-Arg9-BK, in rats that had received either IL-1β (67 and 63%) or TNFα (46 and 35%).

  • Co-injection of the PKC inhibitors, staurosporine (10 nmol) or RO 318220 (30 nmol) inhibited des-Arg9-BK-induced paw oedema (44 and 42% for IL-1β and, 53 and 30% for TNFα, respectively). Genistein (tyrosine kinase inhibitor, 2.5 mg kg−1, s.c.) or PD 098059 (MAP-kinase inhibitor, 30 nmol) produced marked inhibition of des-Arg9-BK-induced oedema (58 and 39% for IL-1β and 31 and 35% for TNFα respectively).

  • The NF-κB inhibitors TLCK (2 mg kg−1, i.p.) and PDCT (100 mg kg−1, i.p.) significantly inhibited the oedema of des-Arg9-BK in IL-1β (27 and 83%) or TNFα (28 and 80%) pre-treated animals.

  • It is concluded that up-regulation of B1 receptors modulated by IL-1β or TNFα involves the release of other cytokines, activation of PKC and tyrosine kinase pathways, co-ordinated with the activation of MAP-kinase and nuclear factor κB, reinforcing the view that B1 receptors may exert a pivotal role in modulating chronic inflammatory processes.

British Journal of Pharmacology (1999) 127, 1851–1859; doi:10.1038/sj.bjp.0702715

Ancillary